Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline
06:38am, Saturday, 24'th Jan 2026
Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to e
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?
09:41am, Wednesday, 21'st Jan 2026
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
12:15pm, Friday, 16'th Jan 2026
AXSM doses the first patient in the phase III FORWARD study testing AXS-14 for fibromyalgia.
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 15'th Jan 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MoneyShow's Best Investment Ideas For 2026: Part 2
04:20pm, Monday, 12'th Jan 2026
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
07:00am, Monday, 12'th Jan 2026
Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively
HALO or AXSM: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 09'th Jan 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Axsome Therapeutics (AXSM). But which of these two stocks offers va
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
08:23am, Thursday, 08'th Jan 2026
Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to
2 Healthcare Stocks to Buy for 2026 and Beyond
05:15am, Thursday, 08'th Jan 2026
Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.
Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM
07:04am, Monday, 05'th Jan 2026
Stanley Laman Group Ltd. acquired a new position in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 17,501 sh
Axsome Therapeutics (NASDAQ:AXSM) Director Mark Saad Sells 37,577 Shares
05:17am, Saturday, 03'rd Jan 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) Director Mark Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The stock was
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
11:55am, Friday, 02'nd Jan 2026
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar?
09:30am, Friday, 02'nd Jan 2026
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug
12:17pm, Wednesday, 31'st Dec 2025
Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.
Axsome Therapeutics Gains on FDA Priority Review for Alzheimer's Treatment
12:14pm, Wednesday, 31'st Dec 2025
Axsome Therapeutics (AXSM) saw its stock surge after the FDA accepted its supplemental New Drug Application (sNDA) for AXS-05 in treating agitation in Alzheimer
